BOC-L-leucine, systematic name (S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-methylpentanoic acid and CAS Registry Number 13139-15-6, is a carbamate-protected L-leucine derivative with molecular formula C₁₁H₂₁NO₄ and molecular weight 231.29 g mol⁻¹. Commercial lots are ordered by this CAS identifier rather than a universal model code; common grades include peptide-synthesis grade, HPLC reference material, and custom bulk starting material. The compound is supplied as a white to off-white crystalline powder with a free carboxylic acid and an acid-labile tert-butoxycarbonyl-protected α-amine, allowing direct activation for peptide-bond formation without exposing the amine until selective deprotection is required. Typical release specifications for peptide-synthesis grade are HPLC purity ≥99.0%, L-enantiomer content ≥99.0%, specific rotation [α]²⁰_D = −25.0° ± 1.0° (c = 1.0, ethanol), loss on drying ≤0.50%, residue on ignition ≤0.10%, and melting range 84–87 °C. The product is not a finished pharmaceutical and is used as a protected chiral building block in solid-phase peptide synthesis and solution-phase fragment condensation.

Table 1 summarizes typical release parameters for a peptide-synthesis-grade material. Values should be confirmed against lot-specific certificates of analysis because analytical methods and acceptance limits differ among manufacturers.

What Limits the Use of BOC-L-leucine in Automated Peptide Synthesis?

In automated solid-phase peptide synthesis using the Boc/benzyl strategy, BOC-L-leucine is usually dissolved to 0.3–0.5 mol L⁻¹ in DMF, NMP, or DCM and activated with a carbodiimide or uronium reagent. A typical coupling cycle in a fitted-glass SPPS reactor of 50–500 mL uses 3–5 equivalents of protected amino acid relative to resin loading, 3–5 equivalents of HBTU or HATU, and 6–10 equivalents of DIPEA; the mixture is stirred by nitrogen bubbling at 20–25 °C for 30–60 min. Coupling completion is checked by the Kaiser ninhydrin test; a residual free amine content above 0.1 mmol g⁻¹ triggers recoupling with 50–100% of the original monomer charge to avoid deletion peptides. This threshold is an operational limit used in preparative SPPS, not an absolute kinetic constant. For difficult sequences containing multiple consecutive leucine residues, double coupling is performed regardless of the Kaiser test when resin loading exceeds 0.5 mmol g⁻¹.

Racemization during activation is suppressed by the carbamate’s electron-withdrawing nitrogen and by short preactivation. When BOC-L-leucine is preactivated with DIC and HOBt in DCM/DMF, the activated ester is formed in 3–15 min at 0–4 °C; the solution should be transferred to the resin immediately because extended standing at 20–25 °C can produce oxazolone intermediates and reduce L-configuration. HOBt or HOAt acts as a racemization suppressant and acyl-transfer catalyst. For carbodiimide-mediated couplings, N-methylmorpholine is sometimes replaced by DIPEA to reduce base-catalyzed racemization in sensitive peptides. Because leucine is not β-branched, the activated monomer is less sterically hindered than Boc-L-valine or Boc-L-isoleucine; coupling rates are therefore higher, and fewer double couplings are required at Leu sites. This difference is significant in hydrophobic clusters where β-branched amino acids restrict resin swelling and slow acyl diffusion.

Published data for continuous-flow packed-bed peptide synthesis with BOC-L-leucine is limited. The established batch data indicate that scale-up from 10 mmol to 1 mol is not linear with respect to mixing time, because more concentrated solutions and thicker resin beds can create temperature gradients and reduce coupling efficiency. In stirred 100 mL to 2 L reactors, uronium activation is often performed at 0–5 °C during reagent addition and then brought to 20–25 °C after monomer activation; jacket cooling is used to dissipate exotherms from the activator solution. Users should record the time between activation and addition, because delayed addition is the most common cause of incomplete coupling and elevated D-isomer content in crude peptide. At 0.5 mol production scale, a recoupling rate below 0.5% of amino acid positions is maintained by Kaiser testing after each cycle; if the test fails at leucine positions, the most common corrective action is to drain, wash with DMF, and recouple with 2 equivalents of Boc-Leu-OH/HOBt/DIC in DCM/DMF at 20–25 °C for 60 min.

Acid Lability, Moisture Sensitivity, and Solvent Compatibility Are the Principal Handling Boundaries

When BOC-L-leucine is exposed to strong acids, the tert-butoxycarbonyl group is released as isobutylene and carbon dioxide after protonation of the carbamate. In Boc/benzyl SPPS, the on-resin deprotection cocktail is often TFA/triisopropylsilane/water 95:2.5:2.5 v/v/v at 20–25 °C for 20–30 min. In solution-phase work, 4 M HCl in dioxane or 50% TFA in DCM is preferred to limit acid burden and reduce the risk of tert-butyl cation alkylation of sensitive residues. If residual TFA remains in the peptide salt after cleavage, the next coupling may be retarded by protonation of the free amine; thorough trituration with diethyl ether or freeze-drying from dioxane is used before the next step.

Solvent and moisture boundaries are significant in anhydrous coupling. At relative humidity above 60%, surface moisture accumulates and can hydrolyze activated esters. Bulk material should be stored in sealed HDPE containers with desiccant at 2–8 °C; before anhydrous coupling, pre-drying at 25–35 °C under vacuum ≤10 mbar until loss on drying is ≤0.50% is recommended. The material should not be exposed to aqueous base for extended periods because the carbamate and the carboxylic acid can both be modified. Strong oxidizers and strong acids should be excluded from storage areas; even trace TFA vapor can initiate premature Boc removal on exposed powder.

Solubility in DMF and DCM supports standard coupling; however, at 0.1 mol L⁻¹ in DMF, clear solutions are maintained at 20–25 °C, while analogous DCM solutions at 0.05 mol L⁻¹ may crystallize below 0 °C. Ethyl acetate and tetrahydrofuran are used for extraction; the free acid is only sparingly soluble in water. During aqueous workup, the product remains in the organic phase if the pH is below 5; at pH above 8, carboxylate salt formation can transfer the material to the aqueous phase. For this reason, hydrochloric acid or citric acid is used to acidify the aqueous phase before extraction.

If Fmoc or Cbz Protection Is Already Established, Orthogonal Replacement Demands Different Deprotection Sequences

In a synthetic route that currently uses Fmoc-L-leucine, direct substitution with BOC-L-leucine is not process-neutral because Fmoc is removed by base and Boc is removed by acid. Fmoc-L-leucine is routinely deprotected with 20% piperidine in DMF at 20–25 °C, conditions that leave Boc intact; however, residual piperidine must be washed out before the subsequent acidic Boc removal, or the acid step can be neutralized and deprotection retarded. Conversely, TFA treatment removes Boc but does not remove Fmoc, so the two protecting groups can be used orthogonally in the same peptide if the sequence of deprotection steps is controlled.

Compared with Cbz-L-leucine, BOC-L-leucine is removed by acid and survives hydrogenolysis. Cbz-L-leucine is removed by catalytic hydrogenation over palladium or by HBr in acetic acid, and the Cbz group is stable to TFA and piperidine. This allows selective deprotection in fragments containing both groups; the Cbz group can be removed under hydrogen while the Boc group remains intact, provided no strong acid is present in the reduction mixture. Conversely, TFA removes the Boc group while the Cbz group remains intact if minimal water is present. This orthogonality is used in solution-phase convergent synthesis of peptides that contain both N-terminal and side-chain amine protection.

The free acid is not the same as Boc-L-leucine N-hydroxysuccinimide ester; the latter is a pre-activated building block used for acylation under mild conditions but is more moisture-sensitive and requires storage at −20 °C. The free acid is preferred when long-term storage stability is more important than rapid acylation. The enantiomeric counterpart Boc-D-leucine has identical molecular weight, melting behavior, and achiral HPLC retention but opposite specific rotation and opposite stereochemical configuration; chiral HPLC or polarimetric release is therefore mandatory. Boc-L-isoleucine and Boc-L-valine share the same Boc chemistry but differ in side-chain topology: L-valine and L-isoleucine are β-branched and exhibit slower carbodiimide-mediated coupling due to steric hindrance, whereas L-leucine, with an isobutyl side chain, couples more readily and is less prone to steric deletion. Boc-L-norleucine has the same molecular formula as BOC-L-leucine but a straight-chain side chain; mass spectrometry alone may not distinguish these isomers, so chromatographic impurity profiling must resolve them. The product is typically supplied in 5 g, 25 g, 100 g, 500 g, and 1 kg lots; batch-to-batch variation in residual ethanol or ethyl acetate can shift loss on drying and should be normalized before stoichiometric use in acylation reactions. Storage under inert, dried atmosphere at 2–8 °C is recommended for long-term use; if the powder is repeatedly opened in humid production areas, the container should be returned to the desiccator and re-analyzed for water content before the next critical coupling.